Larimar Therapeutics reports Q2 net loss of $32.8 million, up from $26.2 million
Larimar Therapeutics reported a second quarter 2026 net loss of $32.8 million, or $0.30 per share, compared with $26.2 million, or $0.41 per share, a year earlier. Operating expenses rose on higher research and development and commercial preparation costs, and the company said it had $156.3 million in cash and marketable securities as of June 30, 2026, with a projected runway into the third quarter of 2027. Shareholders also received an update on the rolling BLA for nomlabofusp, which has its first module submitted, with completion expected in the second half of 2026.
Key points
- Q2 2026 net loss of $32.8 million ($0.30 per share) vs. $26.2 million ($0.41 per share) in Q2 2025
- Q2 2026 research and development expenses of $28.0 million vs. $23.4 million; general and administrative expenses of $6.4 million vs. $4.4 million
- Cash, cash equivalents and marketable securities of $156.3 million as of June 30, 2026, with runway projected into Q3 2027
- Open label study reported 10 participants with anaphylaxis who discontinued the study; first patient dosing in the global confirmatory Phase 3 study expected Q3 2026
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.